Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | HINT1 | P49773 | 4/20 | 0.59 |
| ▸ | NT5E | P21589 | 2/20 | 0.59 |
| ▸ | GSK3A | P49840 | 2/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | PNP | P00491 | 2/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | PDE2A | O00408 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1737326 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL1737325 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL1737322 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL20434874 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL8164012 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL25381419 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| F-Arag SCHEMBL35286 | 0.92 | PDE2A (0.64) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| F-Arag SCHEMBL20581034 | 0.92 | PDE2A (0.64) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| F-Arag SCHEMBL21625251 | 0.92 | PDE2A (0.64) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| F-Arag SCHEMBL16656455 | 0.92 | PDE2A (0.64) | HPGDHINT1NT5EGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20220098198-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| US-11059824-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3505527-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | Invivogen (FR) | 2019-07-03 | — | — | EP | disclosed |
| WO-2017027646-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-6699979-B2 | PREPARED VIA A STEREOSPECIFIC SN2 NUCLEOPHILIC ATTACK OF A PHOSPHODIESTER, OR PHOSPHOROTHIOATE, ON THE 3' POSITION OF A XYLONUCLEOTIDE; USEFUL IN ANTISENSE OR PROBE TECHNOLOGY | ISIS PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
| US-6500945-B2 | BIOSYNTHESIS; STEREOSPECIFIC | ISIS PHARMACEUTICALS, INC. | 2002-12-31 | — | — | US | disclosed |
| US-20020137921-A1 | Oligonucleotides having chiral phosphorus linkages | COOK PHILLIP DAN (US) | 2002-09-26 | — | — | US | disclosed |
| EP-0655088-B1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6239265-B1 | FOR RESEARCH AND DIAGNOSIS | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | disclosed |
| US-5852188-A | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5521302-A | NUCLEOPHILIC REACTION OF PHOSPHATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5212295-A | Monomers for preparation of oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS (US) | 1993-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137921-A1 | Oligonucleotides having chiral phosphorus linkages | RNGTT, PNP, PSPH | HPGD 4579/4885HINT1 424/4885NT5E 434/4885 |
| US-11059824-B2 | Substituted purines as TLR7 agonists | TLR7, TLR9, TLR1 | HPGD 2269/4885HINT1 811/4885NT5E 133/4885 |
| US-12037335-B2 | Substituted purines as TLR7 agonists | TLR7, TLR9, TLR1 | HPGD 2269/4885HINT1 811/4885NT5E 133/4885 |
| US-20220098198-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | TLR7, TLR9, TLR1 | HPGD 2269/4885HINT1 811/4885NT5E 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.